Strattera QTc Concerns Addressed During Review; Lilly Avoids Warning

Lilly's Strattera review provides one example of a successful effort by a sponsor to address potential safety issues for a pending application without agreeing to a risk management program

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet